69 related articles for article (PubMed ID: 38399404)
1. Modification of 4-(4-chlorothiophen-2-yl)thiazol-2-amine derivatives for the treatment of analgesia and inflammation: synthesis and
Mahnashi MH; Rashid U; Almasoudi HH; Nahari MH; Ahmad I; Binshaya AS; Abdulaziz O; Alsuwat MA; Jan MS; Sadiq A
Front Pharmacol; 2024; 15():1366695. PubMed ID: 38487174
[TBL] [Abstract][Full Text] [Related]
2. Experimental investigation and molecular simulations of quinone related compounds as COX/LOX inhibitors.
Chaaban I; Hafez H; Hazzaa A; Domiati S; Abd El Galil KH; Hdeib F; Belal ASF; Ragab H
Inflammopharmacology; 2024 Jun; ():. PubMed ID: 38858336
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, molecular docking evaluation for LOX and COX-2 inhibition and determination of in-vivo analgesic potentials of aurone derivatives.
Ikram M; Shah I; Hussain H; Mughal EU; Naeem N; Sadiq A; Nazir Y; Ali Shah SW; Zahoor M; Ullah R; Ali EA; Umar MN
Heliyon; 2024 May; 10(9):e29658. PubMed ID: 38694111
[TBL] [Abstract][Full Text] [Related]
4. Potential Anticancer Lipoxygenase Inhibitors from the Red Sea-Derived Brown Algae
Alzarea SI; Elmaidomy AH; Saber H; Musa A; Al-Sanea MM; Mostafa EM; Hendawy OM; Youssif KA; Alanazi AS; Alharbi M; Sayed AM; Abdelmohsen UR
Antibiotics (Basel); 2021 Apr; 10(4):. PubMed ID: 33920213
[TBL] [Abstract][Full Text] [Related]
5. Dual acting anti-inflammatory drugs.
Leone S; Ottani A; Bertolini A
Curr Top Med Chem; 2007; 7(3):265-75. PubMed ID: 17305569
[TBL] [Abstract][Full Text] [Related]
6. Sulfadiazine Exerts Potential Anticancer Effect in HepG2 and MCF7 Cells by Inhibiting TNFα, IL1b, COX-1, COX-2, 5-LOX Gene Expression: Evidence from In Vitro and Computational Studies.
Gomaa M; Gad W; Hussein D; Pottoo FH; Tawfeeq N; Alturki M; Alfahad D; Alanazi R; Salama I; Aziz M; Zahra A; Hanafy A
Pharmaceuticals (Basel); 2024 Jan; 17(2):. PubMed ID: 38399404
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and molecular docking of novel pyrazole-chalcone analogs of lonazolac as 5-LOX, iNOS and tubulin polymerization inhibitors with potential anticancer and anti-inflammatory activities.
Ahmed AHH; Mohamed MFA; Allam RM; Nafady A; Mohamed SK; Gouda AE; Beshr EAM
Bioorg Chem; 2022 Dec; 129():106171. PubMed ID: 36166898
[TBL] [Abstract][Full Text] [Related]
8. Novel 1,2,4-triazine-quinoline hybrids: The privileged scaffolds as potent multi-target inhibitors of LPS-induced inflammatory response via dual COX-2 and 15-LOX inhibition.
Ghanim AM; Rezq S; Ibrahim TS; Romero DG; Kothayer H
Eur J Med Chem; 2021 Jul; 219():113457. PubMed ID: 33892270
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of new multitarget-directed ligands containing thienopyrimidine nucleus for inhibition of 15-lipoxygenase, cyclooxygenases, and pro-inflammatory cytokines.
Abdelkhalek AS; Kothayer H; Rezq S; Orabi KY; Romero DG; El-Sabbagh OI
Eur J Med Chem; 2023 Aug; 256():115443. PubMed ID: 37182334
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, inhibitory activity and in silico docking of dual COX/5-LOX inhibitors with quinone and resorcinol core.
Sisa M; Dvorakova M; Temml V; Jarosova V; Vanek T; Landa P
Eur J Med Chem; 2020 Oct; 204():112620. PubMed ID: 32738413
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and biological evaluation of new pyrazoloquinazoline derivatives as dual COX-2/5-LOX inhibitors.
Shaaban MA; Kamal AM; Faggal SI; Farag NA; Aborehab NM; Elsahar AE; Mohamed KO
Arch Pharm (Weinheim); 2020 Nov; 353(11):e2000027. PubMed ID: 32696514
[TBL] [Abstract][Full Text] [Related]
12. A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAF
Ruiz-Saenz A; Atreya CE; Wang C; Pan B; Dreyer CA; Brunen D; Prahallad A; Muñoz DP; Ramms DJ; Burghi V; Spassov DS; Fewings E; Hwang YC; Cowdrey C; Moelders C; Schwarzer C; Wolf DM; Hann B; VandenBerg SR; Shokat K; Moasser MM; Bernards R; Gutkind JS; van 't Veer LJ; Coppé JP
Nat Cancer; 2023 Feb; 4(2):240-256. PubMed ID: 36759733
[TBL] [Abstract][Full Text] [Related]
13. Indisulam targets RNA splicing and metabolism to serve as a therapeutic strategy for high-risk neuroblastoma.
Nijhuis A; Sikka A; Yogev O; Herendi L; Balcells C; Ma Y; Poon E; Eckold C; Valbuena GN; Xu Y; Liu Y; da Costa BM; Gruet M; Wickremesinghe C; Benito A; Kramer H; Montoya A; Carling D; Want EJ; Jamin Y; Chesler L; Keun HC
Nat Commun; 2022 Mar; 13(1):1380. PubMed ID: 35296644
[TBL] [Abstract][Full Text] [Related]
14. Sulfonamide derivatives as potential anti-cancer agents and their SARs elucidation.
Wan Y; Fang G; Chen H; Deng X; Tang Z
Eur J Med Chem; 2021 Dec; 226():113837. PubMed ID: 34530384
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
